Tags

Type your tag names separated by a space and hit enter

Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
J Endocrinol Invest 2014; 37(8):709-714JE

Abstract

PURPOSE

The aim of this study was to evaluate the efficacy of post-operative radioiodine ablation with 1,850 MBq after recombinant human thyrotropin (rhTSH) administration in patients with differentiated thyroid carcinoma (DTC). We also aimed to assess the prognostic role of several patient features on the outcome of ablation.

METHODS

We retrospectively analyzed data from a total of 125 patients with DTC who underwent post-operative radioiodine ablation with 1,850 MBq of ¹³¹I after preparation with rhTSH. One injection of 0.9 mg rhTSH was administered on each of two consecutive days; ¹³¹I therapy was delivered 24 h after the last injection, followed by a post-therapy whole-body scan. Successful ablation was assessed 6-12 months later and defined as an rhTSH-stimulated serum thyroglobulin (Tg) level ≤1.0 ng/ml and a normal neck ultrasound.

RESULTS

Patients were stratified according to the American Thyroid Association (ATA) Management Guidelines for Differentiated Thyroid Cancer. Successful ablation was achieved in 82.4 % of patients, with an ablation rate of 95.1 % in low-risk patients and 76.2 % in intermediate-risk patients. Analyzing the correlation between ablation outcome and patient characteristics, we found a statistically significant association between failure to ablate and class of risk based on ATA guidelines (p = 0.025) and a stimulated Tg value at ablation of above 5 ng/ml (p < 0.001).

CONCLUSION

The use of 1,850 MBq post-operative radioiodine thyroid remnant ablation in association with rhTSH is effective for low- and intermediate-risk patients. Moreover, in our study, we found a statistical correlation between failure to ablate and class of risk based on ATA guidelines for DTC and a stimulated Tg value at ablation.

Authors+Show Affiliations

Unit of Endocrinology, Humanitas Research Hospital, Rozzano, MI, Italy.Unit of Endocrinology, Humanitas Research Hospital, Rozzano, MI, Italy.Nuclear Medicine Department, Humanitas Research Hospital, Via A. Manzoni 56, 20089, Rozzano, MI, Italy.Leyden University, Leiden, The Netherlands.Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Endocrine Unit, Fondazione IRCCS Ca' Granda, Milan, Italy.Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Endocrine Unit, Fondazione IRCCS Ca' Granda, Milan, Italy.Unit of Endocrine Diseases and Diabetology, Ospedale San Giuseppe Multimedica, Milan, Italy. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.Unit of Endocrinology, Humanitas Research Hospital, Rozzano, MI, Italy.Unit of Endocrine Diseases and Diabetology, Ospedale San Giuseppe Multimedica, Milan, Italy. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.Unit of Endocrinology, Humanitas Research Hospital, Rozzano, MI, Italy. Department of Biotechnologies and Translational Medicine, University of Milan, Milan, Italy.Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Endocrine Unit, Fondazione IRCCS Ca' Granda, Milan, Italy.Nuclear Medicine Department, Humanitas Research Hospital, Via A. Manzoni 56, 20089, Rozzano, MI, Italy. arturo.chiti@humanitas.it.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24844565

Citation

Tresoldi, Alberto S., et al. "Radioiodine Ablation With 1,850 MBq in Association With rhTSH in Patients With Differentiated Thyroid Cancer." Journal of Endocrinological Investigation, vol. 37, no. 8, 2014, pp. 709-714.
Tresoldi AS, Sburlati LF, Rodari M, et al. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer. J Endocrinol Invest. 2014;37(8):709-714.
Tresoldi, A. S., Sburlati, L. F., Rodari, M., Schinkelshoek, M. S., Perrino, M., De Leo, S., ... Chiti, A. (2014). Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer. Journal of Endocrinological Investigation, 37(8), pp. 709-714. doi:10.1007/s40618-014-0088-3.
Tresoldi AS, et al. Radioiodine Ablation With 1,850 MBq in Association With rhTSH in Patients With Differentiated Thyroid Cancer. J Endocrinol Invest. 2014;37(8):709-714. PubMed PMID: 24844565.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer. AU - Tresoldi,Alberto S, AU - Sburlati,Laura F, AU - Rodari,Marcello, AU - Schinkelshoek,Mink S, AU - Perrino,Michela, AU - De Leo,Simone, AU - Montefusco,Laura, AU - Colombo,Paolo, AU - Arosio,Maura, AU - Lania,Andrea Gerardo Antonio, AU - Fugazzola,Laura, AU - Chiti,Arturo, Y1 - 2014/05/21/ PY - 2014/03/18/received PY - 2014/04/30/accepted PY - 2014/5/22/entrez PY - 2014/5/23/pubmed PY - 2015/6/24/medline SP - 709 EP - 714 JF - Journal of endocrinological investigation JO - J. Endocrinol. Invest. VL - 37 IS - 8 N2 - PURPOSE: The aim of this study was to evaluate the efficacy of post-operative radioiodine ablation with 1,850 MBq after recombinant human thyrotropin (rhTSH) administration in patients with differentiated thyroid carcinoma (DTC). We also aimed to assess the prognostic role of several patient features on the outcome of ablation. METHODS: We retrospectively analyzed data from a total of 125 patients with DTC who underwent post-operative radioiodine ablation with 1,850 MBq of ¹³¹I after preparation with rhTSH. One injection of 0.9 mg rhTSH was administered on each of two consecutive days; ¹³¹I therapy was delivered 24 h after the last injection, followed by a post-therapy whole-body scan. Successful ablation was assessed 6-12 months later and defined as an rhTSH-stimulated serum thyroglobulin (Tg) level ≤1.0 ng/ml and a normal neck ultrasound. RESULTS: Patients were stratified according to the American Thyroid Association (ATA) Management Guidelines for Differentiated Thyroid Cancer. Successful ablation was achieved in 82.4 % of patients, with an ablation rate of 95.1 % in low-risk patients and 76.2 % in intermediate-risk patients. Analyzing the correlation between ablation outcome and patient characteristics, we found a statistically significant association between failure to ablate and class of risk based on ATA guidelines (p = 0.025) and a stimulated Tg value at ablation of above 5 ng/ml (p < 0.001). CONCLUSION: The use of 1,850 MBq post-operative radioiodine thyroid remnant ablation in association with rhTSH is effective for low- and intermediate-risk patients. Moreover, in our study, we found a statistical correlation between failure to ablate and class of risk based on ATA guidelines for DTC and a stimulated Tg value at ablation. SN - 1720-8386 UR - https://www.unboundmedicine.com/medline/citation/24844565/Radioiodine_ablation_with_1850_MBq_in_association_with_rhTSH_in_patients_with_differentiated_thyroid_cancer_ L2 - https://link.springer.com/article/10.1007/s40618-014-0088-3 DB - PRIME DP - Unbound Medicine ER -